Related Experiment Video
Updated: Jun 24, 2026
08:03
Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes
Published on: June 25, 2017
Glycosphingolipids and insulin resistance
Mirjam Langeveld1, Johannes M F G Aerts
1Department of Endocrinology and Metabolism, Academic Medical Center, Amsterdam, The Netherlands.
Progress in Lipid Research
|March 24, 2009
Summary
Obesity increases insulin resistance risk. Inhibiting glycosphingolipid synthesis improves insulin sensitivity in rodent models, offering a potential treatment for type II diabetes.
Area of Science:
- Metabolic disorders
- Lipid metabolism
- Endocrinology
Background:
- Obesity is linked to insulin resistance, where tissues like liver and muscle respond poorly to insulin.
- Sphingolipids, including ceramides and gangliosides, play a role in developing insulin resistance.
- These lipids can interfere with key insulin signaling pathways, such as Akt phosphorylation and insulin receptor function.
Purpose of the Study:
- To investigate the role of glycosphingolipids in obesity-induced insulin resistance.
- To evaluate the therapeutic potential of inhibiting glycosphingolipid synthesis for improving insulin sensitivity.
Main Methods:
- Utilized rodent models of insulin resistance.
- Investigated the effects of pharmacological inhibition of glycosphingolipid synthesis.
Main Results:
- Ceramide directly inhibits Akt/Protein Kinase B phosphorylation.
- Gangliosides disrupt insulin receptor signaling, potentially by altering membrane localization.
- Pharmacological inhibition of glycosphingolipid synthesis significantly enhanced insulin sensitivity in tested models.
Conclusions:
- Glycosphingolipids are key contributors to insulin resistance in obesity.
- Inhibiting glycosphingolipid synthesis is a promising therapeutic strategy.
- Partial reduction of glycosphingolipids is well-tolerated and could be a novel treatment for type II diabetes.
More Related Videos
Related Concept Videos
01:28Insulin: The Receptor and Signaling Pathways
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Insulin and C-peptide are co-secreted in...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...